Norepinephrine: the next therapeutics frontier for Parkinson's disease

Translational Neurodegeneration

Peter A LeWitt¹ 

[1] Department of Neurology, Henry Ford Hospital and Wayne State University School of Medicine, Detroit, Michigan USA

关键词: neuropharmacology;    Parkinson's disease;    Norepinephrine;   

Others  :  839031
DOI  :  10.1186/2047-9158-1-4

 received in 2011-12-06, accepted in 2012-01-13,  发布年份 2012

【 摘 要 】

Tissue concentrations of norepinephrine (NE) are markedly decreased in various regions of the Parkinson's disease (PD) brain. As in the substantia nigra pars compacta, neuronal dropout and Lewy bodies are prominent changes affecting the locus coeruleus, which is the source of ascending NErgic projections. Despite the major roles of NE throughout the brain, there has been only minimal exploration of pharmacological intervention with NErgic neurotransmission. Cognitive operations, "freezing" of gait, tremor, dyskinesia, REM sleep regulation, and other aspects of brain function are tied into signaling by NE, and there is also evidence that it may have a role in the neurodegenerative process itself. This article reviews the reported pharmacological experience in PD therapeutics.

【 授权许可】

   
2012 LeWitt; licensee BioMed Central Ltd.

【 参考文献 】

• [1]Gesi M, Soldani P, Giorgi FS, et al.: The role of the locus coeruleus in the development of Parkinson's disease. Neurosci Biobehav Rev 2000, 24:655-668.
• [2]Agid Y, Javoy-Agid F, Ruberg M: Biochemistry of neurotransmitters in Parkinson's disease. In Movement Disorders 2. Edited by Marsden CD, Fahn S. New York: Butterworths; 1987:166-230.
• [3]Hurst JH, LeWitt PA, Burns RS, Foster NL, Lovenberg W: CSF dopamine β-hydroxylase activity in Parkinson's disease. Neurology 1985, 35:565-568.
• [4]Chan-Palay V, Asan A: Alterations in catecholamine neurons of the locus coeruleus in senile dementia of the Alzheimer type and in Parkinson's disease with and without dementia and depression. J Comp Neurol 1989, 287:373-392.
• [5]Benarroch EE: The locus coeruleus norepinephrine system: functional organization and potential clinical significance. Neurology 2009, 73:1699-1704.
• [6]Greenfield JG, Bosanquet FD: The brainstem lesions in Parkinsonism. J Neurol Neurosurg Psychiatry 1953, 16:213-226.
• [7]Del Tredici K, Rüb U, De Vos RA, Bohl JR, Braak H: Where does Parkinson disease pathology begin in the brain? J Neuropathol Exp Neurol 2002, 61:413-426.
• [8]Götz ME, Künig G, Riederer P, Youdim MB: Oxidative stress: free radical production in neural degeneration. Pharmacol Ther 1994, 63:37-122.
• [9]Hirsch EC, Hunot S: Neuroinflammation in Parkinson's disease: a target for neuroprotection? Lancet Neurol 2009, 8:382-397.
• [10]Rommelfanger KS, Weinshenker D: Norepinephrine: the redheaded stepchild of Parkinson's disease. Biochem Pharmacol 2007, 74:177-190.
• [11]Mavridis M, Colpaert FC, Millan MJ: Differential modulation of (+)- amphetamine-induced rotation in unilateral substantia nigra-lesioned rats by alpha-1 as compared to alpha 2 agonists and antagonists. Brain Res 1991, 562:216-224.
• [12]Marien M, Briley M, Coplaert F: Noradrenaline exacerbates MPTP-induced striatal dopamine loss in mice. Eur J Pharmacol 1993, 236:487-489.
• [13]Fornai F, Bassi L, Torracca MT, Scalori V, Corsini GU: Norepinephrine loss exacerbates methamphetamine-induced striatal dopamine depletion in mice. Eur J Pharmacol 1995, 283:99-102.
• [14]Kilbourn MR, Sherman P, Abbott LC: Reduced MPTP toxicity in striatum of the mutant mouse tottering. Synapse 1998, 30:205-210.
• [15]Grenhoff J, Nisell M, Ferre S, et al.: Noradrenergic modulation of midbrain dopamine cell firing elicited by stimulation of the locus coeruleus in the rat. J Neural Transm Gen Sect 1993, 93:11-25.
• [16]Foster NL, Newman RP, LeWitt PA, et al.: Peripheral beta-adrenergic blockade treatment of Parkinsonian tremor. Ann Neurol 1984, 16:505-508.
• [17]Carpentier AF, Bonnet AM, Vidhailhet M, Agid Y: Improvement of levodopainduced dyskinesia by propranolol in Parkinson's disease. Neurology 1996, 46:1548-1551.
• [18]Rascol O, Arnulf I, Peyro-Saint Paul H, et al.: Idoxozan, an alpha-2 antagonist, and L-DOPA-induced dyskinesias in patients with Parkinson's disease. Clin Neuropharmacol 2001, 16:708-713.
• [19]LeWitt PA, Hauser RA, Lu M, et al.: Fipamezole in the treatment of dyskinesias in advanced Parkinson disease (FJORD study). Neurology 2011, in press.
• [20]Mathias CJ: L-dihydroxyphenylserine (droxidopa) in the treatment of orthostatic hypotension: the European experience. Clin Auton Res 2008, 18(suppl 1):25-29.
• [21]Narabayashi H, Nakanishi T, Kanazawa I, et al.: Clinical effects of L-threo-3,4-dihydroxyphenylserine in Parkinson's disease and Parkinson syndrome: results of multi-center open study at 45 institutions. Yakuri To Chiryo [Japan Pharmacol Ther; in Japanese] 1987, 15(suppl 2):411-443.
• [22]Bédard MA, el Massioui F, Malapani C, et al.: Attentional deficits in Parkinson's disease: partial reversibility with naphtoxazine (SDZ NVI-085), a selective noradrenergic alpha 1 agonist. Clin Neuropharm 1998, 21:108-117.
• [23]Riekkinen M, Jäkälä P, Kejonen K, Riekkinen P Jr: The alpha2 agonist, clonidine, improves spatial working performance in Parkinson's disease. Neuroscience 1999, 92:983-989.
• [24]Marsh L, Biglan K, Gerstenhaber M, Williams JR: Atomoxetine for the treatment of executive dysfunction in Parkinson's disease: a pilot open-label study. Mov Disord 2009, 24:277-282.
• [25]Dubois B, Pillon B: Cognitive deficits in Parkinson's disease. J Neurol 1997, 244:2-8.
• [26]Remy P, Doder M, Lees A, Turjanski N, Brooks D: Depression in Parkinson's disease: loss of dopamine and noradrenaline innervations in the limbic system. Brain 2005, 128:1314-1322.
• [27]Pintor L, Baillès E, Valldeoriola F, et al.: Response to 4-month treatment with reboxetine in Parkinson's disease patients with a major depressive episode. Gen Hosp Psychiatry 2006, 28:59-64.